Solventum Corporation · NYSE:SOLV
Solventum — Q3 2026 Earnings Presentation
15 slides from Solventum's earnings presentation, Nov 5, 2026
Slide 1: Q3 FY26 Earnings presentation
Q3 FY26 Earnings presentation November 5, 2026 © Solventum 2026. All rights reserved.
Slide 2: Forward-looking statements and use of document
Forward-looking statements and use of document This presentation contains or incorporates by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. All statements that reflect Solventum’s expectation
Slide 3: Solventum | roadmap to the mission
Solventum | roadmap to the mission Values Strategic pillars Put people first Be a best & preferred Mission place to work Win with excellence Enabling better, Solve what matters smarter, safer Be a trusted partner healthcare to Advance together improve lives Be a top quartile Live with heart performe
Slide 4: Solventum value creation formula
Solventum value creation formula Attractive set up diverse businesses, attractive markets and strong brands Foundational + enhancements mission, talent, culture, innovation engine (commercial and R&D) market selection and growth drivers – enable sales growth, + Strategic clarity margin expansion and
Slide 5: Key Messages for the Quarter
Key Messages for the Quarter Continuing to Spin-off deliver on separation work commitments largely complete Growth Increased full- strengthening year 2026 across the adjusted EPS portfolio guidance Q3 FY2026 Earnings Presentation © Solventum 2026. All rights reserved. 5
Slide 6: Q3 FY26 financial summary
Q3 FY26 financial summary Dental Solutions Key metrics $317M (6.7)% Reported GAAP Non-GAAP3 (7.4)% Organic Operating margin 3.5% 19.9% Health Information Systems TOTAL SOLVENTUM SALES1 MedSurg $356M $1,211M Diluted EPS $(0.07) $1.45 +3.3% Reported +4.4% Organic $1,949M +0.4% Reported (7.0)% Y/Y Repo
Slide 7: MedSurg summary
MedSurg summary AWC $528M | 43.6% +8.9% Y/Y Rep +1.5% Y/Y Org $1,211M Q3 financial results +0.4% Y/Y Reported (2.8)% Y/Y Organic* IP&SS Q3 FY26 Q3 FY25 Y/Y* $683M | 56.4% (5.3)% Y/Y Rep (5.7)% Y/Y Org Reported +0.4% FDA 510k clearance for combined Net sales $1,211M $1,206M Organic (2.8)% Restrata an
Slide 8: Dental Solutions summary
Clinpro Clear Fluoride Dental Solutions summary Treatment Provides effective fluoride uptake with lower dosage. Water-based, rosin-free Q3 financial results formula that’s ready to apply and provides protection to enamel and dentin surfaces. This fluoride treatment features a ready- release formula t
Slide 9: Health Information Systems summary
Health Information Systems summary Solventum System 360 Encompass Latest generation coding solution combines coding and reimbursement processes along Q3 financial results with workflow improvements to help hospitals streamline revenue cycle processes, receive accurate reimbursement, Q3 FY26 Q3 FY25
Slide 10: Executing a balanced capital plan
Executing a balanced capital plan Debt paydown Invest for growth Return capital to shareholders • Divested P&F business1; net proceeds • Executing multi-year ‘Transform for the • YTD, repurchased 5.3M shares for primarily used for debt paydown Future’ initiative. Expect to generate ~$400M in aggrega
Slide 11: FY2026 financial guidance and considerations
FY2026 financial guidance and Additional 2026 considerations considerations FX impact net sales ~100bps benefit Toward the high end of Operating Margin Organic sales growth 2.5% to 3.0% Toward the high end of 22.2% to 22.7% Ex-SKU 3.5% to 4.0% Reflects 120bps benefit from IEEPA tariff refund Adjuste
Slide 12: Appendix
Appendix Q3 FY2026 Earnings Presentation © Solventum 2026. All rights reserved. 12
Slide 13: Non-GAAP financial measures
Non-GAAP financial measures In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance. The adjusted measures are not in accordance with, nor are they
Slide 14: Q3 FY26 non-GAAP reconciliation & free cash flow
Q3 FY26 non-GAAP reconciliation & free cash flow 3M Spin-off & Q3 FY26 Restructuring separation-related Certain litigation- Acquisition and Q3 FY26 ($ Millions, except per share data) GAAP Amortization costs costs related costs divestiture-related non-GAAP Net sales 1,949 1,949 Gross margin 1,062 11
Slide 15: Glossary and definitions
Glossary and definitions Abbreviation Elaboration Organic sales growth Total net sales less the impacts of foreign currency and sales from business acquisitions or AI Artificial intelligence divestitures for the first 12 months post-transaction AWC Advanced Wound Care Adjusted gross margin Gross mar